D H Epstein1, K L Preston. 1. Clinical Pharmacology and Therapeutics Branch, Treatment Section, National Institute on Drug Abuse/Intramural Research Program, National Institutes of Health, Baltimore, MD 21224, USA. depstein@intra.nida.nih.gov
Abstract
AIMS: To determine whether cannabinoid-positive urine specimens in heroin-dependent out-patients predict other drug use or impairments in psychosocial functioning, and whether such outcomes are better predicted by cannabis-use disorders than by cannabis use itself. DESIGN: Retrospective analyses of three clinical trials; each included a behavioral intervention (contingency management) for cocaine or heroin use during methadone maintenance. Trials lasted 25-29 weeks; follow-up evaluations occurred 3, 6 and 12 months post-treatment. For the present analyses, data were pooled across trials where appropriate. SETTING: Urban out-patient methadone clinic. PARTICIPANTS: Four hundred and eight polydrug abusers meeting methadone-maintenance criteria. MEASUREMENTS: Participants were categorized as non-users, occasional users or frequent users of cannabis based on thrice-weekly qualitative urinalyses. Cannabis-use disorders were assessed with the Diagnostic Interview Schedule III-R. Outcome measures included proportion of cocaine- and opiate-positive urines and the Addiction Severity Index (at intake and follow-ups). FINDINGS: Cannabis use was not associated with retention, use of cocaine or heroin, or any other outcome measure during or after treatment. Our analyses had a power of 0.95 to detect an r2 of 0.11 between cannabis use and heroin or cocaine use; the r2 we detected was less than 0.03 and non-significant. A previous finding, that cannabis use predicted lapse to heroin use in heroin-abstinent patients, did not replicate in our sample. However, cannabis-use disorders were associated weakly with psychosocial problems at post-treatment follow-up. CONCLUSIONS: Cannabinoid-positive urines need not be a major focus of clinical attention during treatment for opiate dependence, unless patients report symptoms of cannabis-use disorders.
AIMS: To determine whether cannabinoid-positive urine specimens in heroin-dependent out-patients predict other drug use or impairments in psychosocial functioning, and whether such outcomes are better predicted by cannabis-use disorders than by cannabis use itself. DESIGN: Retrospective analyses of three clinical trials; each included a behavioral intervention (contingency management) for cocaine or heroin use during methadone maintenance. Trials lasted 25-29 weeks; follow-up evaluations occurred 3, 6 and 12 months post-treatment. For the present analyses, data were pooled across trials where appropriate. SETTING: Urban out-patientmethadone clinic. PARTICIPANTS: Four hundred and eight polydrug abusers meeting methadone-maintenance criteria. MEASUREMENTS: Participants were categorized as non-users, occasional users or frequent users of cannabis based on thrice-weekly qualitative urinalyses. Cannabis-use disorders were assessed with the Diagnostic Interview Schedule III-R. Outcome measures included proportion of cocaine- and opiate-positive urines and the Addiction Severity Index (at intake and follow-ups). FINDINGS: Cannabis use was not associated with retention, use of cocaine or heroin, or any other outcome measure during or after treatment. Our analyses had a power of 0.95 to detect an r2 of 0.11 between cannabis use and heroin or cocaine use; the r2 we detected was less than 0.03 and non-significant. A previous finding, that cannabis use predicted lapse to heroin use in heroin-abstinent patients, did not replicate in our sample. However, cannabis-use disorders were associated weakly with psychosocial problems at post-treatment follow-up. CONCLUSIONS:Cannabinoid-positive urines need not be a major focus of clinical attention during treatment for opiate dependence, unless patients report symptoms of cannabis-use disorders.
Authors: G M Miele; K M Carpenter; M Smith Cockerham; K D Trautman; J Blaine; D S Hasin Journal: Drug Alcohol Depend Date: 2000-04-01 Impact factor: 4.492
Authors: Mohammadali Mojarrad; Jeffrey H Samet; Debbie M Cheng; Michael R Winter; Richard Saitz Journal: Drug Alcohol Depend Date: 2014-06-18 Impact factor: 4.492
Authors: Wilfrid Noel Raby; Kenneth M Carpenter; Jami Rothenberg; Adam C Brooks; Huiping Jiang; Maria Sullivan; Adam Bisaga; Sandra Comer; Edward V Nunes Journal: Am J Addict Date: 2009 Jul-Aug
Authors: Kevin P Hill; Heather E Bennett; Margaret L Griffin; Hilary S Connery; Garrett M Fitzmaurice; Geetha Subramaniam; George E Woody; Roger D Weiss Journal: Drug Alcohol Depend Date: 2013-03-22 Impact factor: 4.492